PloS one, 2022-02, Vol.17 (2), p.e0264254
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models
- Ist Teil von
- PloS one, 2022-02, Vol.17 (2), p.e0264254
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2022
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Bone abnormalities affect all individuals with Down syndrome (DS) and are linked to abnormal expression of DYRK1A, a gene found in three copies in people with DS and Ts65Dn DS model mice. Previous work in Ts65Dn male mice demonstrated that both genetic normalization of Dyrk1a and treatment with ~9 mg/kg/day Epigallocatechin-3-gallate (EGCG), the main polyphenol found in green tea and putative DYRK1A inhibitor, improved some skeletal deficits. Because EGCG treatment improved mostly trabecular skeletal deficits, we hypothesized that increasing EGCG treatment dosage and length of administration would positively affect both trabecular and cortical bone in Ts65Dn mice. Treatment of individuals with DS with green tea extract (GTE) containing EGCG also showed some weight loss in individuals with DS, and we hypothesized that weights would be affected in Ts65Dn mice after EGCG treatment. Treatment with ~20 mg/kg/day EGCG for seven weeks showed no improvements in male Ts65Dn trabecular bone and only limited improvements in cortical measures. Comparing skeletal analyses after ~20mg/kg/day EGCG treatment with previously published treatments with ~9, 50, and 200 mg/kg/day EGCG showed that increased dosage and treatment time increased cortical structural deficits leading to weaker appendicular bones in male mice. Weight was not affected by treatment in mice, except for those given a high dose of EGCG by oral gavage. These data indicate that high doses of EGCG, similar to those reported in some treatment studies of DS and other disorders, may impair long bone structure and strength. Skeletal phenotypes should be monitored when high doses of EGCG are administered therapeutically.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0264254Titel-ID: cdi_plos_journals_2632135032
- Format
- –
- Schlagworte
- Abnormalities, Animal models, Animals, Biology, Biology and Life Sciences, Bones, Cancellous bone, Care and treatment, Catechin, Catechin - administration & dosage, Catechin - adverse effects, Catechin - analogs & derivatives, Catechin - therapeutic use, Child development, Complications and side effects, Cortical bone, Dosage, Down syndrome, Down Syndrome - drug therapy, Down Syndrome - metabolism, Down's syndrome, Drug Administration Schedule, Dyrk Kinases, Epigallocatechin gallate, Epigallocatechin-3-gallate, Experiments, Female, Females, Fractures, Gene expression, Green tea, Kinases, Laboratory animals, Long bone, Male, Males, Medicine and Health Sciences, Mice, Muscle, Skeletal - drug effects, Muscle, Skeletal - metabolism, Osteoporosis, Patient outcomes, Phenotypes, Protein Serine-Threonine Kinases - antagonists & inhibitors, Protein Serine-Threonine Kinases - genetics, Protein Serine-Threonine Kinases - metabolism, Protein-Tyrosine Kinases - antagonists & inhibitors, Protein-Tyrosine Kinases - genetics, Protein-Tyrosine Kinases - metabolism, Research and Analysis Methods, Rodents, Tea, Transgenic animals, Weight loss